RxDoctor Payments Data

Tahir Naeem, MD

Internal Medicine · Okeechobee, FLNPI 1801820337

Payments from drug & device makers

$828in general payments, 2019–2025

Across 49 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$159
  • AstraZeneca$119
  • GSK$96
  • Novo Nordisk$65
  • Lilly USA, LLC$50
  • Pfizer$49
  • plus $289 from 12 others

What the payments were for

  • Food & beverage$70485%
  • Education$12315%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$828 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$692,619
Medicare patients
785
Services billed
9,743

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban935$433,357
Trelegy ElliptaFluticasone/Umeclidin/Vilanter172$214,905
MounjaroTirzepatide124$159,943
XareltoRivaroxaban236$138,497
Tresiba Flextouch U-200Insulin Degludec130$127,734
XifaxanRifaximin64$121,612
EntrestoSacubitril/Valsartan154$73,119
TrulicityDulaglutide53$70,372
JardianceEmpagliflozin114$66,153
Tresiba Flextouch U-100Insulin Degludec139$58,580
OzempicSemaglutide38$52,553
Breo ElliptaFluticasone/Vilanterol80$46,809
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog271$34,923
ArexvyRsvpref3 Antigen/As01e/Pf112$33,595
FarxigaDapagliflozin Propanediol35$31,719

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$49$447,445981 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Shingrix, Incruse Ellipta$96$322,450464 claims
Lilly USA, LLCMounjaro, Trulicity$50$230,315177 claims
Johnson & JohnsonXarelto$32$138,497236 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat, Tradjenta$21$121,351181 claims
Novo NordiskOzempic, Rybelsus$65$74,49952 claims
NovartisEntresto$29$73,119154 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$119$71,48083 claims
Astellas Pharma US IncMyrbetriq$159$26,20170 claims
AbbVieVraylar$37$13,35721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Okeechobee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →